Annals of Intensive Care · 2022 · 34 citations · 25 references
PharmacyPharmacokineticsPharmacologyPharmacokinetic ModelingPopulation PharmacokineticsSepsisCompartmental Pharmacokinetic ModelsPharmacokinetic SimulationPharmacokinetics In Critical IllnessPharmacokinetics Of AntimicrobialsSepsis PharmacotherapySeptic ShockContinuous Renal Replacement Therapy ClearanceContinuous Renal Replacement Therapy PharmacokineticsOne-compartment EliminationOne-compartment Pharmacokinetic ModelsPharmacokinetic Population ModelingPharmacokinetics Of Antimicrobial AgentsPopulation-based Pharmacokinetic ModelingSepsis Pharmacokinetics
Abstract Background Hemadsorption of cytokines is used in critically ill patients with sepsis or septic shock. Concerns have been raised that the cytokine adsorber CytoSorb ® unintentionally adsorbs vancomycin. This study aimed to quantify vancomycin elimination by CytoSorb ® . Methods Critically ill patients with sepsis or septic shock receiving continuous renal replacement therapy and CytoSorb ® treatment during a prospective observational study were included in the analysis. Vancomycin pharmacokinetics was characterized using population pharmacokinetic modeling. Adsorption of vancomycin by the CytoSorb ® was investigated as linear or saturable process. The final model was used to derive dosing recommendations based on stochastic simulations. Results 20 CytoSorb ® treatments in 7 patients (160 serum samples/24 during CytoSorb ® -treatment, all continuous infusion) were included in the study. A classical one-compartment model, including effluent flow rate of the continuous hemodialysis as linear covariate on clearance, best described the measured concentrations (without CytoSorb ® ). Significant adsorption with a linear decrease during CytoSorb ® treatment was identified (p < 0.0001) and revealed a maximum increase in vancomycin clearance of 291% (initially after CytoSorb ® installation) and a maximum adsorption capacity of 572 mg. For a representative patient of our cohort a reduction of the area under the curve (AUC) by 93 mg/L*24 h during CytoSorb ® treatment was observed. The additional administration of 500 mg vancomycin over 2 h during CytoSorb ® attenuated the effect and revealed a negligible reduction of the AUC by 4 mg/L*24 h. Conclusion We recommend the infusion of 500 mg vancomycin over 2 h during CytoSorb ® treatment to avoid subtherapeutic concentrations. Trial registration NCT03985605. Registered 14 June 2019, https://clinicaltrials.gov/ct2/show/NCT03985605
25
Anand Kumar, Daniel Roberts, Kenneth E. Wood et al. · Critical Care Medicine · 2006 · 6.1K citations
Veterinary Medicine, Infectious Diseases, Antimicrobial Pharmacotherapy +13
Michael J. Rybak, Jennifer Lê, Thomas P. Lodise et al. · American Journal of Health-System Pharmacy · 2020 · 1.1K citations · Full text